High Levels of the MDM2 Oncogene in Paediatric Rhabdomyosarcoma Cell Lines May Confer Multidrug Resistance

Overview

Journal Br J Cancer

Specialty Oncology

Date 2001 Dec 18

PMID 11742497

Citations 8

Authors

H A Cocker

S M Hobbs

N Tiffin

K Pritchard-Jones

C R Pinkerton

L R Kelland

Affiliations

Soon will be listed here.

Abstract

The MDM2 protein is known to be overexpressed in some sarcomas including rhabdomyosarcoma. However, the extent to which the MDM2 protein influences sensitivity to chemotherapeutic drugs is unclear. We have analysed this further using stable transfection of the mdm2 gene into 4 well-characterised human paediatric rhabdomyosarcoma cell lines. Transfection with the mdm2 gene resulted in increased levels of the MDM2 protein in all the cell lines. In 2 of the lines, SCMC and RD, the mdm2 gene caused between 2-fold and 61-fold increase in resistance to vincristine, etoposide and doxorubicin but not to cisplatin. In these lines there was an increase in expression of the mdr-1 gene which encodes P-glycoprotein, but not the mrp1 gene which encodes the multidrug resistance protein (MRP). The resistance was reversible using the MDR modulator PSC833, confirming the presence of P-glycoprotein. We conclude that MDM2 overexpression may be a mechanism by which multidrug resistance is regulated in some rhabdomyosarcomas.

Citing Articles

Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.

Kowalczyk J, Wan X, Hernandez E, Luo R, Lyons G, Wilson K Mol Cancer Ther. 2020; 20(2):307-319.

PMID: 33158997 PMC: 7867632. DOI: 10.1158/1535-7163.MCT-20-0525.

Molecular Characterization of a Rare Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation in a 24 Year Old.

Olson N, Gularte-Merida R, Selenica P, Da Cruz Paula A, Alemar B, Weigelt B Int J Surg Pathol. 2019; 28(4):454-463.

PMID: 31801397 PMC: 8302235. DOI: 10.1177/1066896919890401.

The palladacycle complex AJ-5 induces apoptotic cell death while reducing autophagic flux in rhabdomyosarcoma cells.

Bleloch J, du Toit A, Gibhard L, Kimani S, Ballim R, Lee M Cell Death Discov. 2019; 5:60.

PMID: 30701092 PMC: 6349869. DOI: 10.1038/s41420-019-0139-9.

Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.

Xie X, Lozano G, Siddik Z Oncogene. 2016; 35(36):4798-806.

PMID: 26876197 PMC: 5289310. DOI: 10.1038/onc.2016.12.

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.

Abdi J, Chen G, Chang H Oncotarget. 2013; 4(12):2186-207.

PMID: 24327604 PMC: 3926819. DOI: 10.18632/oncotarget.1497.

References

Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M, Tominaga T . Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res. 1998; 89(2):221-7. PMC: 5921757. DOI: 10.1111/j.1349-7006.1998.tb00552.x. View

Leveillard T, Wasylyk B . The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. J Biol Chem. 1998; 272(49):30651-61. DOI: 10.1074/jbc.272.49.30651. View

Hobbs S, Jitrapakdee S, Wallace J . Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun. 1998; 252(2):368-72. DOI: 10.1006/bbrc.1998.9646. View

Ashcroft M, Vousden K . Regulation of p53 stability. Oncogene. 2000; 18(53):7637-43. DOI: 10.1038/sj.onc.1203012. View

Cocker H, Pinkerton C, Kelland L . Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. Br J Cancer. 2000; 83(3):338-45. PMC: 2374566. DOI: 10.1054/bjoc.2000.1273. View

Taylor A, Shu L, Danks M, Poquette C, Shetty S, Thayer M . P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol. 2000; 35(2):96-103. DOI: 10.1002/1096-911x(200008)35:2<96::aid-mpo2>3.0.co;2-z. View

Peng Y, Chen L, Li C, Lu W, Agrawal S, Chen J . Stabilization of the MDM2 oncoprotein by mutant p53. J Biol Chem. 2001; 276(9):6874-8. DOI: 10.1074/jbc.C000781200. View

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

Chan H, Thorner P, Haddad G, Ling V . Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol. 1990; 8(4):689-704. DOI: 10.1200/JCO.1990.8.4.689. View

10.

Chin K, Ueda K, Pastan I, Gottesman M . Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992; 255(5043):459-62. DOI: 10.1126/science.1346476. View

11.

Barrand M, Wright K, Rabbitts P, Twentyman P . A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst. 1994; 86(2):110-7. DOI: 10.1093/jnci/86.2.110. View

12.

Sharp S, Rowlands M, Jarman M, Kelland L . Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br J Cancer. 1994; 70(3):409-14. PMC: 2033360. DOI: 10.1038/bjc.1994.319. View

13.

Bordow S, Haber M, Madafiglio J, Cheung B, Marshall G, Norris M . Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 1994; 54(19):5036-40. View

14.

Kuttesch J, Parham D, Luo X, Meyer W, Bowman L, Shapiro D . P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol. 1996; 14(3):886-900. DOI: 10.1200/JCO.1996.14.3.886. View

15.

Keleti J, Quezado M, Abaza M, Raffeld M, Tsokos M . The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol. 1996; 149(1):143-51. PMC: 1865219. View

16.

Meddeb M, Valent A, Danglot G, Nguyen V, Duverger A, Fouquet F . MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). Cytogenet Cell Genet. 1996; 73(4):325-30. DOI: 10.1159/000134368. View

17.

Kondo S, Kondo Y, Hara H, Kaakaji R, Peterson J, Morimura T . mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer. 1996; 74(8):1263-8. PMC: 2075914. DOI: 10.1038/bjc.1996.527. View

18.

Naito M, Tsuruo T . New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother Pharmacol. 1997; 40 Suppl:S20-4. DOI: 10.1007/s002800051056. View

19.

Tanner B, Hengstler J, Laubscher S, MEINERT R, Oesch F, Weikel W . mdm 2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer. 1997; 74(4):438-42. DOI: 10.1002/(sici)1097-0215(19970822)74:4<438::aid-ijc13>3.0.co;2-5. View

20.

Thottassery J, Zambetti G, Arimori K, Schuetz E, Schuetz J . p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A. 1997; 94(20):11037-42. PMC: 23579. DOI: 10.1073/pnas.94.20.11037. View